Cover Image
市場調查報告書

白血病治療藥的全球市場:2016∼2020年

Global Leukemia Therapeutics Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 372068
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
白血病治療藥的全球市場:2016∼2020年 Global Leukemia Therapeutics Market 2016-2020
出版日期: 2016年09月20日 內容資訊: 英文 110 Pages
簡介

全球白血病治療藥市場,預計2016∼2022以8.44%的年複合成長率擴大。

本報告提供全球白血病治療藥市場相關調查,市場現狀及成長預測,市場規模,各地區趨勢,及主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 產品研發線

第6章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 白血病治療藥的全球市場:各疾病市場區隔

第8章 全球CLL治療藥市場

第9章 全球ALL治療藥市場

第10章 全球AML治療藥市場

第11章 全球CML治療藥市場

第12章 白血病治療藥的全球市場:各地區市場區隔

  • 各地區市場
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第13章 白血病治療藥的全球市場:推動市場的要素

  • 藥物的特別法律規章指定
  • 白血病監測的技術性進步
  • 適應擴大認證的申請

第14章 促進要素的影響

第15章 白血病治療藥的全球市場:課題

  • 複雜的預後
  • 財務及基礎設施上的規定
  • 目前治療方法相關限制
  • 診斷的延遲

第16章 促進要素與課題的影響

第17章 白血病治療藥的全球市場:市場趨勢

第18章 供應商環境

  • 競爭模式
  • 其他值得注意的供應商

第19章 主要供應商分析

  • F. Hoffmann-La Roche
  • Novartis
  • Bristol-Myers Squibb
  • AbbVie
  • Teva Pharmaceuticals

第20章 附錄

第21章 關於Technavio

目錄
Product Code: IRTNTR10286

About Leukemia

Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.

Technavio's analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche
  • Novartis
  • Bristol-Myers Squibb
  • AbbVie
  • Teva Pharmaceuticals

Other Prominent Vendors

  • Altor BioScience
  • Amgen
  • ARIAD Pharmaceuticals
  • Arno Therapeutics
  • Astex Pharmaceuticals
  • AstraZeneca
  • Baxter Healthcare
  • Bayer HealthCare
  • Bellicum Pharmaceuticals
  • Biogen
  • Boehringer Ingelheim
  • BioLineRx
  • Boston Biomedical
  • Celator Pharmaceuticals
  • Celgene
  • CTI BioPharma
  • Chroma Therapeutics
  • Chugai Pharmaceutical
  • Cyclacel Pharmaceuticals
  • Daiichi Sankyo
  • Eisai
  • Emergent BioSolutions
  • Erytech Pharma
  • Fate Therapeutics
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • iDD biotech
  • Immune Pharmaceuticals
  • Immunomedics
  • Infinity Pharmaceuticals
  • Innate Pharma
  • Jazz Pharmaceuticals
  • Juno Therapeutics
  • Karyopharm Therapeutics
  • Ligand Pharmaceuticals
  • MEDA Pharmaceuticals
  • MedImmune
  • Merck
  • Midas Pharma
  • Molecular Templates
  • MorphoSys
  • Nippon Shinyaku
  • Novo Nordisk
  • Onconova Therapeutics
  • Ono Pharmaceuticals
  • Orphan Europe
  • Otsuka
  • Pfizer
  • Portola Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Sanofi
  • Sigma-Tau Pharmaceuticals
  • Stemline Therapeutics
  • Sunesis Pharmaceuticals
  • TG Therapeutics
  • TheraMAB
  • Tolero Pharmaceuticals
  • XEME Biopharma
  • Xencor
  • ZIOPHARM Oncology

Market driver

  • Technological advances in the monitoring of leukemia
  • For a full, detailed list, view our report

Market challenge

  • Limitations associated with current therapeutic options
  • For a full, detailed list, view our report

Market trend

  • Rise in the development of combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation by disease type

PART 08: Global CLL therapeutics market

  • Market overview
  • Total addressable market for global CLL therapeutics
  • Vendors in the market

PART 09: Global ALL therapeutics market

  • Market overview
  • Vendors in the market

PART 10: Global AML therapeutics market

  • Market overview
  • Vendors in the market

PART 11: Global CML therapeutics market

  • Market overview
  • Vendors in the market

PART 12: Geographical segmentation

  • Global leukemia therapeutics market by geography 2015-2020
  • Leukemia therapeutics market in Americas
  • Leukemia therapeutics market in EMEA
  • Leukemia therapeutics market in APAC

PART 13: Market drivers

  • Special regulatory designations for drugs
  • Technological advances in the monitoring of leukemia
  • Application for expanded indication approvals

PART 14: Impact of drivers

PART 15: Market challenges

  • Complicated disease prognosis
  • Financial and infrastructural constraints
  • Limitations associated with current therapeutic options
  • Delay in diagnosis

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Rise in the development of combination therapies
  • Patient assistance programs
  • Focus on the identification of targets for the development of new therapies

PART 18: Vendor landscape

  • Competitive scenario
  • Other prominent vendors

PART 19: Key vendor analysis

  • F. Hoffmann-La Roche
  • Novartis
  • Bristol-Myers Squibb
  • AbbVie
  • Teva Pharmaceuticals

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Timeline of development of leukemia drugs
  • Exhibit 03: Impact of key customer segments on market 2015
  • Exhibit 04: Key buying criteria for global leukemia therapeutics market 2015
  • Exhibit 05: Pipeline portfolio: Global CLL therapeutics market
  • Exhibit 06: Pipeline portfolio: Global CML therapeutics market
  • Exhibit 07: Pipeline portfolio: Global ALL therapeutics market
  • Exhibit 08: Pipeline portfolio: Global AML therapeutics market
  • Exhibit 09: Global leukemia therapeutics market snapshot: Developed and emerging markets 2015
  • Exhibit 10: Distribution of people aged 60 years and over (millions)
  • Exhibit 11: Global leukemia therapeutics market 2015-2020 ($ billions)
  • Exhibit 12: Global leukemia therapeutics market segmentation: Growth cycle analysis
  • Exhibit 13: Five forces analysis
  • Exhibit 14: Segmentation of global leukemia therapeutics market by type of disease 2015
  • Exhibit 15: Global leukemia therapeutics market by type of disease 2015-2020
  • Exhibit 16: Global leukemia therapeutics market segmentation: Growth lifecycle analysis
  • Exhibit 17: Global CLL therapeutics market 2015-2020 ($ billions)
  • Exhibit 18: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
  • Exhibit 19: Major vendors in the CLL therapeutics market 2015
  • Exhibit 20: Global ALL therapeutics market 2015-2020 ($ billions)
  • Exhibit 21: Major vendors in ALL therapeutics market 2015
  • Exhibit 22: Global AML therapeutics market 2015-2020 ($ millions)
  • Exhibit 23: Major vendors in global AML therapeutics market
  • Exhibit 24: Global CML therapeutics market 2015-2020 ($ billions)
  • Exhibit 25: Major vendors in global CML therapeutics market
  • Exhibit 26: Global leukemia therapeutics market by geography 2015-2020
  • Exhibit 27: Percentage share of global leukemia therapeutics market by geography 2015 and 2020
  • Exhibit 28: Global share of leukemia therapeutics market by geography 2015
  • Exhibit 29: Revenue of global leukemia therapeutics market by geography 2015-2020 ($ billions)
  • Exhibit 30: Revenue/growth outlook in different countries/regions 2015
  • Exhibit 31: Global leukemia therapeutics market segmentation by region: Market growth lifecycle analysis 2015
  • Exhibit 32: Leukemia therapeutics market in different regions by type of disease
  • Exhibit 33: Opportunity analysis of leukemia therapeutics market in Americas
  • Exhibit 34: Percentage share of new cases of leukemia in US 2014
  • Exhibit 35: Hispanic population percentage in US total population
  • Exhibit 36: Leukemia therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 37: Opportunity analysis of leukemia therapeutics market in EMEA
  • Exhibit 38: Leukemia therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 39: Opportunity analysis of leukemia therapeutics market in APAC
  • Exhibit 40: Leukemia therapeutics market in APAC 2015-2020 ($ billions)
  • Exhibit 41: Orphan designation pipeline drugs for leukemia
  • Exhibit 42: Breakthrough therapy designation drugs for leukemia
  • Exhibit 43: Expanded indication approval drugs in the treatment of leukemia
  • Exhibit 44: Impact of drivers
  • Exhibit 45: Cost of therapy for some leukemia drugs
  • Exhibit 46: Impact of drivers and challenges
  • Exhibit 47: Combination therapies under development for the treatment of leukemia
  • Exhibit 48: Leukemia drugs with patient assistance programs
  • Exhibit 49: Key vendors ranking 2015
  • Exhibit 50: Geographical presence of key vendors in leukemia therapeutics market 2015
  • Exhibit 51: Competitive landscape of vendors in global leukemia therapeutics market 2015-2020
  • Exhibit 52: F. Hoffmann-La Roche: Profile
  • Exhibit 53: F. Hoffmann-La Roche: Strength analysis
  • Exhibit 54: F. Hoffmann-La Roche: Growth strategy matrix
  • Exhibit 55: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 56: F. Hoffmann-La Roche: YoY revenue and growth rate of Rituxan/MabThera 2013-2015 ($ billions)
  • Exhibit 57: F. Hoffmann-La Roche: Rituxan/MabThera geographic segmentation by revenue 2015
  • Exhibit 58: Novartis: Profile
  • Exhibit 59: Novartis: Strength analysis
  • Exhibit 60: Novartis: Growth strategy matrix
  • Exhibit 61: Novartis: Opportunity assessment
  • Exhibit 62: Bristol-Myers Squibb: Profile
  • Exhibit 63: Bristol-Myers Squibb: Strength analysis
  • Exhibit 64: Bristol-Myers Squibb: Growth strategy matrix
  • Exhibit 65: Bristol-Myers Squibb: Opportunity assessment
  • Exhibit 66: AbbVie: Profile
  • Exhibit 67: AbbVie: Strength analysis
  • Exhibit 68: AbbVie: Growth strategy matrix
  • Exhibit 69: AbbVie: Opportunity assessment
  • Exhibit 70: Teva Pharmaceuticals: Profile
  • Exhibit 71: Teva Pharmaceuticals: Strength analysis
  • Exhibit 72: Teva Pharmaceuticals: Growth strategy matrix
  • Exhibit 73: Teva Pharmaceuticals: Opportunity assessment
  • Exhibit 74: Teva Pharmaceuticals: YoY revenue and growth rate of TREANDA 2013-2015 ($ millions)
Back to Top